Dr. Kory on The People’s Convoy
Dr. Pierre Kory joins Eric Bolling at Newsmax to discuss the the People's Convoy trucking from coast-to-coast for medical freedom.
The FLCCC News Capsule —May 8, 2022
The Children's Health Defense organized an all day panel at the Ohio State House on Wednesday, May 4 to promote medical freedom to Ohio legislators. Our Drs. Paul Marik and Pierre Kory were participants on the panel.
“The White House is Promoting a Drug Questionable for Acute Treatment”
FLCCC founder and Chief Scientific Officer, Dr. Paul Marik, analyzes CDC-approved COVID-19 treatments on The Absolute Truth.
Nurses on the Changing Face of Healthcare
FLCCC's Kristina Morros and Kimberly Overton, founder of Nurse Freedom Network, discuss the challenges nurses face in a post-pandemic world.
Veteran Nurse Uses Ivermectin to Recover from Long COVID
Patti Gilliano, a nurse with 35 years of experience, got severe COVID in 2020 and went to the emergency room for help. She asked the doctor about ivermectin but on that visit and then the next one, the doctor refused.
Prioritizing Effective COVID-19 Treatments Globally
This week, Dr. Pierre Kory’s powerful Op-Ed for The Brownstone Institute called for advancing global access to medicines with the most effective treatment as the universal goal.
Early Ivermectin Use: A Couple’s COVID Recovery Story
Cody and Catey had a good friend who told them all about ivermectin and the I-MASK+protocols. They started taking the recommended doses as soon as they started feeling unwell.
Matt Zebell is 74 and Beat COVID with Early Treatment
Watch as Matt explains how he kept a diary of his COVID experience and believes that early treatment is the key to beating COVID.
Ask the Docs
For this week’s webinar, we opened the floor up to the audience for Q&A on Paxlovid, ivermectin and a lot more
Revamping our Dysfunctional Drug Approval Process
In a guest editorial for the Brownstone Institute, Dr. Pierre Kory examines Big Pharma's pay-to-play conflict of interest "sponsoring" research to recommend expensive, on-patent, drugs instead of cheaper, generic alternatives.
